DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia

Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pneumonia, Pneumocystis Carinii; HIV Infections

Intervention: Atovaquone (Drug)

Phase: N/A

Status: Completed

Sponsored by: Glaxo Wellcome


To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80.

Clinical Details

Official title: A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia

Study design: Masking: Open Label, Primary Purpose: Treatment


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria Patients must have the following:

- Clinical diagnosis of acute mild to moderate Pneumocystis carinii pneumonia.

- Dose-limiting intolerance to TMP / SMX or inadequate response to TMP / SMX.

- Willingness and ability to give informed consent. The clinical condition of the

patient and appropriate physiologic criteria should be used in evaluating patients for therapy with 566C80. Patients who are rapidly progressing in disease severity or have severe disease as evidenced by sustained tachypnea (e. g., sustained respiratory rate > 30 breaths/minute), rapid deterioration in (A-a)DO2 and chest radiograph may not be appropriate candidates for oral therapy, including 566C80. Therapy with parenteral pentamidine should be undertaken in these cases. Treatment with IV trimetrexate or primaquine / clindamycin should be considered for these patients unless the patient is known to have dose-limiting intolerance to these agents. Patients with severe PCP who are intolerant and/or unresponsive to therapy with TMP / SMX and parenteral pentamidine may enroll in the 566C80 open-label compassionate plea protocol. Exclusion Criteria Patients with the following prior conditions are excluded: History of serious or dose-limiting adverse experience during previous 566C80 therapy, thought to be attributable to the drug.

Locations and Contacts

Glaxo Wellcome Inc, Research Triangle Park, North Carolina 27709, United States
Additional Information

Last updated: June 23, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017